EU, AstraZeneca Publish Redacted Contract in Vaccine Dispute

The AstraZeneca office building in Brussels, on Friday. (AP Photo/Francisco Seco)

BRUSSELS (AP) — The European Union and AstraZeneca agreed Friday to make public a heavily redacted version of their coronavirus vaccine agreement, which lies at the heart of a dispute over how many shots the pharmaceutical company should be supplying the EU’s 27 nations.

The contract, agreed to last year by the European Commission and the drugmaker, allows the EU’s member countries to buy 300 million doses of the AstraZeneca vaccine, with an option for a further 100 million doses. It’s one of several contracts the EU’s executive branch has with vaccine makers to secure a total of more than 2 billion shots.

As part of an “advanced purchase agreement” with vaccine companies, the EU said it has invested 2.7 billion euros ($3.8 billion), including 336 million ($408 million) to finance the production of AstraZeneca’s serum at four factories.

But the EU lashed out at the British-Swedish drugmaker this week after it said it would not be able to deliver the 80 million doses that it hoped to provide initially and could only supply 31 million. Brussels claimed AstraZeneca would supply even less than that, just one-quarter of the doses due between January and March, and, member countries began to complain.

The European Commission, which is the EU”s executive arm, is concerned that doses meant for Europe might have been diverted from an AstraZeneca plant on the continent to the United Kingdom, where two other company sites are located. The EU also wants doses at two sites in Britain to be made available to European citizens.

AstraZeneca CEO Pascal Soriot told Germany’s Die Welt newspaper this week that the U.K. government helped create the vaccine developed with Oxford University and signed its contract three months before the EU did. Soriot said that under the British contract, vaccines produced at U.K. sites must go to the U.K. first.

The “advanced purchasing agreement” with the EU was signed in August, before the Oxford-AstraZeneca vaccine had been properly tested. The European Medicines Agency approved the vaccine on Friday, making it the third authorized for use by EU nations.

Much of the 41-page document made public was blacked out, making it very difficult to establish which side is in the right. Details about the price of the vaccine were notably redacted. The U.K. is thought to be paying far more for the vaccine than EU countries.

An EU official said 95% of the blackened text is a result of requests from AstraZeneca.

Asked about details concerning the heart of the row – exactly how many doses were promised to be delivered to the EU and when -European Commission spokesman Eric Mamer said: “We cannot give you the numbers, they have been redacted from the contract.”

To the uninitiated, the contract is not easily understood. However, it is laden with references to a “Best Reasonable Effort” being made on items like deliveries and volumes, given the uncertainty surrounding the development of the vaccine when it was drafted.

AstraZeneca might say only it can decide whether it’s doing its best, but the EU argues that this is a legal term and that only a judge can decide whether the company has made a “Best Reasonable Effort,” meaning the truth of the matter might lay in the hands of the two sides’ lawyers.

To head off similar disputes and allay fears that vaccines might be diverted, the Commission introduced measures Friday to tighten rules on the exports of shots produced in the 27 EU countries. The “vaccine export transparency mechanism” will be used until the end of March to control vaccine shipments to non-EU countries and to ensure that any exporting company based in the EU first submits its plans to national authorities.

The EU insisted the measure is not an export ban. Officials said it is intended to ensure member nations get the shots they bought from vaccine producers. They said the mechanism would not affect humanitarian deliveries and shipments to countries covered by the COVAX initiative co-led by the World Health Organization, which, a program created to ensure less-wealthy parts of the world have equitable access to COVID-19 vaccines.

In addition to the dispute with AstraZeneca, delays or production problems with the Pfizer-BioNTech vaccine have caused a political uproar across the EU.

Nearly two weeks after France extended its vaccine campaign to people over 75 years old, elderly residents in Paris are flocking to vaccination centers amid fears that daily injection rates will soon drop because of a vaccine shortfall.

In Italy, virus czar Domenico Arcuri blasted the delivery delays, which he said had so far deprived the country of 300,000 doses and drastically slowed down its campaign to inoculate older adults.

Arcuri said drugmaker Moderna had joined Pfizer and AstraZeneca in announcing delays, saying the pharmaceutical company had advised the Italian government of a 20% cut in planned deliveries of the Moderna vaccine the week of Feb. 8.

“A vaccine is not a soft drink or a snack,” Arcuri said. “With all due respect to soft drinks and snacks, the vaccine is the only antidote to get out of this (dark) night that has lasted a year.”


By LORNE COOK and SAMUEL PETREQUIN Associated Press
Nicole Winfield in Rome and Thomas Adamson in Paris contributed.

Exit mobile version